COMP <GO>
AXGN vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Axogen Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: AXGN 6
— JNJ 6
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: AXGN
LAST: $49.37 (-0.52%) • MKT CAP: $2.96B
balance-sheet
18.64
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXGN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXGN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.30% | 67.90% | +6.40 | AXGN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.60% | 25.50% | -28.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.10% | 2.97% | -3.07 | JNJ | /fcf-yield <GO> |
| Operating Margin | -3.50% | 34.70% | -38.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -7.00% | 28.50% | -35.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | 6.00% | +14.20 | AXGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 18.64 | 5.59 | +13.05 | AXGN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 73.9 | 60.4 | +13.58 | AXGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.08 | +0.02 | AXGN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 23.0x | -5.00 | AXGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.96B | $662.49B | -$659.53B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXGN REV | JNJ REV | AXGN GROSS % | JNJ GROSS % | AXGN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $225.2M | $94.19B | 74.3% | 67.9% | -$2.9M | $19.70B |
| FY 2024 | $187.3M | $88.82B | 75.8% | 69.1% | $1.4M | $19.84B |
| FY 2023 | $159.0M | $85.16B | 44.0% | 44.0% | -$12.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXGN // BETA 1.10
JNJ // BETA 1.08